Key result
Clemizole potently blocks hERG channels and prolongs QTc intervals in isolated guinea pig hearts.
Why the study?
The potential effects of clemizole on cardiac potassium currents and cardiac repolarization were not previously investigated.
Does clemizole block cardiac potassium currents and prolong the QT interval in preclinical models?
Does clemizole block cardiac potassium currents and prolong the QT interval in preclinical models?
Effect estimate: IC50: 0.07 μM
Clemizole potently blocks hERG channels and delays cardiac repolarization, indicating a potential risk for QT prolongation and arrhythmias.
Raises concern for QT-related arrhythmias with clemizole; leaves open confirmation in clinical settings.
Background and Purpose Clemizole, a histamine H1 receptor antagonist has a potential therapeutic effect on hepatitis C infection and also potently inhibits TRPC5 ion channels. The aim of the present study was to investigate whether clemizole blocks cardiac K+ currents and thus affects cardiac repolarization. Experimental Approach Whole‐cell patch techniques was used to examine the effects of clemizole on hERG channel current, IKs and Kv1.5 channel current in HEK 293 cell expression systems as well as on ventricular action potentials of guinea pig hearts. Isolated hearts from guinea pigs were used to determine the effect on the ECG. Key Results Clemizole decreased hERG current by blocking both open and closed states of the channel in a concentration‐dependent manner (IC50: 0.07 μM). The S631A, S636A, Y652A and F656V hERG mutant channels reduced the inhibitory effect of clemizole (IC50: 0.82, 0.89, 1.49 and 2.98 μM, respectively), suggesting that clemizole is a pore blocker of hERG channels. Clemizole also moderately decreased IKs and human Kv1.5 channel current. Moreover, clemizole increased the duration of the ventricular action potential in guinea pig hearts and the QTc interval in isolated perfused hearts from guinea pigs, in a concentration‐dependent manner (0.1–1.0 μM). Conclusion and Implications Our results provide the first evidence that clemizole potently blocks hERG channels, moderately inhibits cardiac IKs, delays cardiac repolarization and thereby prolongs QT interval. Thus, caution should be taken when clemizole is used as a TRPC5 channel blocker or for treating hepatitis C infection.
No takes yet. Share an insight, caveat, or question.
Jie et al. (2016) studied this question. Clemizole was evaluated on hERG channel current inhibition (IC50: 0.07 μM). Clemizole potently blocked hERG channels (IC50: 0.07 μM), moderately inhibited cardiac IKs, and prolonged the QTc interval in isolated guinea pig hearts in a concentration-dependent manner.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: